非布司他治疗痛风患者的效果好吗？

Medically, gout is a type of hyperuricemia (HUA) and is a common disease in endocrinology. Hyperuricemia is a metabolic disease caused by excessive production of uric acid in the body or decreased uric acid excretion. The main ingredient of febuxostat is febuxostat, whose chemical name is 2-[(3-cyano-4-isobutoxy)phenyl]-4-methyl-5-thiazolecarboxylic acid. As a xanthine oxidase (XO) inhibitor, febuxostat has a significant inhibitory effect on both oxidized and reduced XOR, so its effect of reducing uric acid is more powerful and lasting. Therefore, febuxostat (febuxostat, feburic) can be used to treat chronic hyperuricemia in gout.

Is febuxostat effective in treating gout patients?

A phase III clinical trial compared the efficacy of febuxostat (80 and 120 mg/d) and allopurinol (300 mg/d) in parallel. A 1-year study of 760 patients showed that compared with the allopurinol group, more patients in the febuxostat (febuxostat, feburic) group achieved the main trial efficacy indicator - the sUA concentration was measured below 60 mg/L in the last 3 months (all subjects were gout patients, and the pre-trial sUA concentrations were all above 80 mg/L); after 52 weeks of treatment, febuxostat (febuxostat, feburic) failed to significantly improve Reduce the area of tophi (tophi is an aggregate of urate crystals unique to gout), but this effect was more obvious in the high-dose group early in the trial; in each treatment group, patients with sUA concentrations reaching the target (<60mg/L) were less likely to have gout attacks, and their tophi area was more significantly reduced; adverse reactions and their incidence rates were similar in each treatment group, including abnormal liver function, diarrhea, headache, joint-related signs and symptoms, and musculoskeletal/connective tissue symptoms.